PS-Targeting Antibodies as Anti-Cancer Agents

Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

Research has shown that chemotherapy and radiation increase the exposure of PS on the surface of the tumor blood vessels, increasing the availability of bavituximab's target molecule, and potentially enhancing bavituximab's anti-tumor activity.

Click here to learn about our bavituximab oncology clinical trials.

Read more about bavituximab's anti-tumor mechanism of action...